Anzeige
Mehr »
Login
Mittwoch, 28.07.2021 Börsentäglich über 12.000 News von 669 internationalen Medien
Countdown: Die derzeit größte Kurswette mit Ansage!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 855526 ISIN: JP3160400002 Ticker-Symbol: EII 
Tradegate
27.07.21
20:13 Uhr
71,00 Euro
-2,00
-2,74 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
EISAI CO LTD Chart 1 Jahr
5-Tage-Chart
EISAI CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
70,0072,5015:01
70,0072,0014:51

Aktuelle News zur EISAI Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:07Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC5
EISAI Aktie jetzt für 0€ handeln
DiDWS Invest SDG Global Equities LD-Fonds: 06/2021-Bericht, Eisai Co. neu ins Portfolio aufgenommen321Frankfurt (www.fondscheck.de) - Der Aktienfonds DWS Invest SDG Global Equities LD (ISIN LU1891311430/ WKN DWS2Y8) investiert in Unternehmen, die einen positiven Beitrag zur Erreichung mindestens eines...
► Artikel lesen
DiBiogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021337- Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer's disease - Presentations include an assessment of...
► Artikel lesen
MoBiogen Inc.: Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021328Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer's disease Presentations include an assessment of...
► Artikel lesen
FrEisai, Merck's Drug Combo Approved for Advanced Endometrial Cancer5
FrFDA approves Merck, Eisai's Keytruda and Lenvima combination for endometrial cancer3
FrEisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma445Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient...
► Artikel lesen
DoOnce conditional, Merck's Keytruda, Eisai's Lenvima win full approval for endometrial cancer2
DoMerck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer1
DoThe Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO10
DoMerck, Eisai's Keytruda/Lenvima regimen scores full approval in endometrial cancer2
21.07.Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021440TOKYO, July 21, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta...
► Artikel lesen
19.07.Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand337TOKYO, July 19, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic...
► Artikel lesen
13.07.Eisai pushes second Alzheimer's drug despite call to probe U.S. approval of first4
01.07.Eisai and Lilly among top H1 gainers in big pharma as Viatris and Merck trail59
01.07.Eisai shares rise after DAYVIGO's Hong Kong launch4
01.07.Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong225First Launch For Dayvigo In Asia Outside Of JapanTOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered...
► Artikel lesen
24.06.Eisai-Biogen Alzheimer's drug gets FDA breakthrough designation37
24.06.Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)366An Anti-amyloid Beta Protofibril Antibody for The Treatment Of Alzheimer's DiseaseTOKYO, June 24, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug...
► Artikel lesen
24.06.Eisai's drug for Alzheimer's with Biogen gets breakthrough status in U.S14
Seite:  Weiter >>
140 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1